MEK and the inhibitors: from bench to bedside-Reference-Cited by-同舟云学术

MEK and the inhibitors: from bench to bedside

Published:2013-04-12 Issue:1 Volume:6 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Akinleye Akintunde,Furqan Muhammad,Mukhi Nikhil,Ravella Pavan,Liu Delong

Abstract

Abstract Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

https://link.springer.com/content/pdf/10.1186/1756-8722-6-27.pdf

Reference115 articles.

1. Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature. 2001, 410 (6824): 37-40.

2. Thompson N, Lyons J: Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol. 2005, 5 (4): 350-356.

3. Hsueh C-T, Liu D, Wang H: Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomarker Res. 2013, 1 (1): 1-

4. Furqan M, Mukhi N, Lee B, Liu D: Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Res. 2013, 1 (1): 5-

5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011, 364 (26): 2507-2516.

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment;International Journal of Molecular Sciences;2024-01-23

2. A MEK inhibitor arrests the cell cycle of human conjunctival fibroblasts and improves the outcome of glaucoma filtration surgery;Scientific Reports;2024-01-22

3. Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma;Cancer Letters;2024-01

4. Discovery of pyrazolo[3,4-d]pyrimidines as novel mitogen-activated protein kinase kinase 3 (MKK3) inhibitors;Bioorganic & Medicinal Chemistry;2024-01

5. High In Vitro and In Vivo Activity of BI-847325, a Dual MEK/Aurora Kinase Inhibitor, in Human Solid and Hematologic Cancer Models;Cancer Research Communications;2023-10-25